Raily Aesthetic Medicine International Holdings Limited stock analysis
Want to see HK:2135 full AI Analyst Report?
The reported 36.7% revenue-growth measure indicates meaningful top-line expansion over the measured period. If sustained, stronger revenue can improve operating leverage, support investment in the aesthetic medicine platform, and reinforce the company’s ability to build scale over the next several quarters.
Returning to profitability after heavy losses marks an important operational improvement and reduces immediate dependence on external funding. The rebound in gross and EBITDA margins provides a foundation for earnings recovery, although the durability of that improvement still depends on maintaining cost discipline.
Strong positive operating and free cash flow in 2025 shows that the business generated cash internally rather than relying solely on accounting earnings or financing. This improves funding flexibility for operations and investment, while providing a more durable cushion if growth opportunities require capital.
A net margin of roughly 1% leaves limited protection against cost increases, weaker demand, or modest operating setbacks. Even after the turnaround, small changes in revenue or expenses could eliminate earnings, making the current profit base less durable than the margin recovery suggests.
Several consecutive loss-making years indicate that the business has not yet demonstrated a consistently repeatable earnings model. This history raises the risk that the 2025 improvement reflects a fragile recovery rather than a permanently higher profit base, particularly given stated sensitivity to demand and costs.
The sharp improvement in 2025 is encouraging, but earlier negative operating cash flow and inconsistent conversion show that cash generation has not been dependable across the cycle. That variability can constrain reinvestment and weaken resilience if operating conditions deteriorate again.
Raily Aesthetic Medicine International Holdings Limited ( ($HK:2135) ) has provided an update. Raily Aesthetic Medicine International Holdings Limited has cancelled all 47,276,437 outstanding share options previously granted under its
The latest update is out from Raily Aesthetic Medicine International Holdings Limited ( ($HK:2135) ). Raily Aesthetic Medicine International Holdings Limited reported a sharp improvement in performance for the six
Raily Aesthetic Medicine International Holdings Limited ( ($HK:2135) ) has shared an update. Raily Aesthetic Medicine International Holdings Limited, a Hong Kong-listed provider of aesthetic medical services and equipment, operates
Raily Aesthetic Medicine International Holdings Limited ( ($HK:2135) ) has provided an announcement. Raily Aesthetic Medicine International Holdings reported that all resolutions at its 2026 annual general meeting in Hangzhou
Raily Aesthetic Medicine International Holdings Limited ( ($HK:2135) ) has provided an announcement. Raily Aesthetic Medicine International Holdings Limited has updated investors on a change in the planned use of
Raily Aesthetic Medicine International Holdings Limited ( ($HK:2135) ) has provided an announcement. Raily Aesthetic Medicine International Holdings Limited plans to amend its existing second amended and restated memorandum and
An announcement from Raily Aesthetic Medicine International Holdings Limited ( ($HK:2135) ) is now available. Raily Aesthetic Medicine International Holdings reported revenue of RMB189.4 million for 2025, a slight decline
Raily Aesthetic Medicine International Holdings Limited is an investment holding company primarily engaged in providing a comprehensive range of cosmetic medical services. Its operations are structured into three principal segments: Aesthetic Medical Services, Consulting Services, and the distribution of Aesthetic Medical Equipment Products. The company's service offerings include various aesthetic procedures such as: Surgical interventions: encompassing cosmetic surgeries performed on different areas of the face or body. Minimally invasive treatments: largely consisting of aesthetic injection procedures. Aesthetic dermatology: featuring diverse energy-based treatments. Aesthetic dental care: including orthodontic services, dental implants, and teeth whitening. Management consulting: providing specialized advisory services for aesthetic medical practices. Furthermore, Raily trades in medical equipment and sells surgical implants alongside aesthetic medical skincare products. The company manages and operates a network of four private, for-profit aesthetic medical clinics located in China's Zhejiang and Anhui Provinces. It serves a diverse clientele, including individual retail customers and other aesthetic medical institutions. Founded in 2008 and headquartered in Hangzhou, People's Republic of China, Raily Aesthetic Medicine International Holdings Limited operates as a subsidiary of Ruide Consultation Limited.
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 3 | 14 |
| Technical Analysis | 5 | 2 | 3 |
| Moving Averages | 0 | 1 | 11 |
